{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:51:15Z","timestamp":1762458675825},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,10,27]],"date-time":"2008-10-27T00:00:00Z","timestamp":1225065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,10,27]],"date-time":"2008-10-27T00:00:00Z","timestamp":1225065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1038\/bmt.2008.349","type":"journal-article","created":{"date-parts":[[2008,10,27]],"date-time":"2008-10-27T14:25:45Z","timestamp":1225117545000},"page":"509-511","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen"],"prefix":"10.1038","volume":"43","author":[{"given":"M","family":"Magni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Devizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Tarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Parvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,27]]},"reference":[{"key":"BFbmt2008349_CR1","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, Wormann B, Durshen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008349_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","volume":"16","author":"AS Freedman","year":"1998","unstructured":"Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC et al. High-dose chemoradiotherapy and anti B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16: 13\u201318.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008349_CR3","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/sj.bmt.1703296","volume":"29","author":"AM Gianni","year":"2002","unstructured":"Gianni AM, Cortelazzo S, Magni M, Martelli M, Tarella C, Patti K et al. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002; 29: S10\u2013S13.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008349_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558\u2013565.","journal-title":"Blood"},{"key":"BFbmt2008349_CR5","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","volume":"12","author":"M Ladetto","year":"2006","unstructured":"Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Bl Marr Transplant 2006; 12: 1270\u20131276.","journal-title":"Biol Bl Marr Transplant"},{"key":"BFbmt2008349_CR6","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","volume":"8","author":"L Fayad","year":"2007","unstructured":"Fayad L, Thomas D, Romaguera J . Update of the M.D. Anderson Cancer Center experience with hyper-CVAD and Rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymph Myel 2007; 8: S57\u2013S62.","journal-title":"Clin Lymph Myel"},{"key":"BFbmt2008349_CR7","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a non-randomized phase-II multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687\u20132693.","journal-title":"Blood"},{"key":"BFbmt2008349_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O Determan","year":"2008","unstructured":"Determan O, Hoster E, Ott G, Bernd HW, Loddenkemper C, Hansman ML et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385\u20132387.","journal-title":"Blood"},{"key":"BFbmt2008349_CR9","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Brad SK, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"BFbmt2008349_CR10","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P et al. Phase II trial of single-agent Temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347\u20135356.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2008349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2008349","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2008349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T11:07:53Z","timestamp":1648033673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2008349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,27]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["BFbmt2008349"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2008.349","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2008,10,27]]},"assertion":[{"value":"27 October 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}